Compounds useful as inhibitors of ATR kinase
US10392391B2 · kind B2 · utility
Assignee
Inventors
- Nadia Ahmad
- Dean Boyall
- Jean-Damien Charrier
- Chris Davis
- Rebecca Davis
- Steven Durrant
- Gorka Etxebarria I Jardi
- Damien Fraysse
- Juan-Miguel Jimenez
- David Kay
- Ronald Knegtel
- Donald Middleton
- Michael O'Donnell
- Maninder Panesar
- Francoise Pierard
- Joanne Pinder
- David Matthew Shaw
- Pierre-Henri Storck
- John Studley
- Heather Twin
Key dates
| Filing date | Jun 26, 2017 |
| Grant date | Aug 27, 2019 |
| Priority date | — |
| Expiry date | Jun 26, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.